Merck reported Q1 sales of $15.8 billion, beating estimates, with cancer drug Keytruda driving growth. Company raised full-year revenue and EPS forecasts.
Discover Bristol Myers Squibb's impressive first-quarter performance, with revenues exceeding expectations driven by key products like Eliquis and Reblozyl. Despite challenges, the company aims for significant cost savings and future growth.
Strategic Education Inc (NASDAQ:STRA) gains momentum with a 13.1% year-on-year sales surge to $290.300 million in Q1 FY24, surpassing analyst predictions. Notably, total costs and expenses decrease by 3.6%, fueling a robust operating margin of 14.2%. CEO Karl McDonnell attributes the success to strong growth in the U.S. Higher Education segment, buoyed by employer-affiliated enrollment, and robust performance in Education Technology Services, including Sophia subscriptions.